Noopept vs NSI-189
A side-by-side research comparison of Noopept and NSI-189 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Noopept | NSI-189 |
|---|---|---|
| Full name | Noopept (GVS-111) | NSI-189 Phosphate (Neurogenic Compound) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Investigational |
| Mechanism | Metabolized to cycloprolylglycine which modulates AMPA/NMDA receptors. Increases NGF and BDNF in hippocampus/cortex. Antioxidant neuroprotection and acetylcholine enhancement. | Stimulates hippocampal neural stem cell proliferation and differentiation via Akt/CREB/BDNF signaling. Increases hippocampal volume visible on MRI. |
| Molecular weight | 318.4 Da | 366.4 Da |
| Half-life | 30-60 minutes (active metabolite longer) | 18-22 hours |
| Bioavailability | High (oral/sublingual) | High (oral) |
| Typical dose | 10-30 mg | 40-80 mg |
| Frequency | 2-3x daily | Once daily |
| Route | Oral or Sublingual | Oral |
Noopept reported benefits
- Enhanced memory/learning
- Neuroprotection
- BDNF/NGF increase
- Improved focus
- Anxiolytic
- Low dose requirement
NSI-189 reported benefits
- Hippocampal neurogenesis
- Measurable brain volume increase
- Cognitive enhancement
- Antidepressant effects
- Long-term neural benefit
Related comparisons
Research and educational reference only. Not medical advice.